Read More

PureTech Health Reports Imbrium Therapeutics Exercised License Option Under R&D Collab For LYT-503/IMB-150 For Interstitial Cystitis/Bladder Pain Syndrome; PureTech Receives $6.5M, Is Eligible For Added $53M In Milestones

Imbrium Therapeutics has paid PureTech $6.5 million and PureTech is eligible to receive up to $53 million in additional development milestone payments for this program in addition to royalties on product sales Imbrium

PRTC